by 
Chronic kidney disease drugs are used for slowing the progression of kidney damage and decreasing clinical complications in patients with Chronic Kidney Disease (CKD). Drugs classes covered in this market are ACE inhibitors, calcium channel blockers, beta-blockers, erythropoiesis-stimulating agents (ESAs), vitamin D analogs, phosphate binders, and others.
The global Chronic Kidney Disease Drugs Market is estimated to be valued at US$ 13,220.0 Mn in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the chronic kidney disease drugs market is the rising number of pipeline drugs. Many innovative drugs are under development targeting different mechanisms involved in chronic kidney disease progression. For instance, FibroGen’s roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, has received approval for the treatment of anemia due to chronic kidney disease in China and Japan. Also, Ardelyx’s tenapanor, a NHE3 inhibitor, is approved by FDA for the control of serum phosphorus levels in adult patients with CKD.
SWOT Analysis
Strength: The chronic kidney disease drugs market share has a strong pipeline of drugs in late stages of clinical development. Many key players are investing heavily in R&D to develop novel therapeutics.
Weakness: High cost of chronic kidney disease treatment poses a major challenge. The drugs available are also associated with side effects.
Opportunity: Rising Geriatric population is increasing the risk of chronic kidney disease. Growing awareness about early diagnosis and management of kidney diseases also provides opportunities.
Threats: Stringent regulations for drug approval and patent expiry of blockbuster drugs are major threats. Alternative treatment options like dialysis also pose competition.
Key Takeaways
The global chronic kidney disease drugs market size was valued at US$ 13,220.0 Mn in 2023 and is expected to reach US$ 18,990.0 Mn by 2030, expanding at a CAGR of 4.5% during the forecast period. The high prevalence of diabetes and hypertension, major risk factors for kidney diseases, is expected to drive the market.
Regional analysis: North America dominated the global market in 2023 and is expected to continue its dominance over the forecast period as well. This is attributed to the increasing incidence of CKD, access to optimal treatment options, and presence of major market players in the region. Asia Pacific is anticipated to witness the highest CAGR during the analysis period owing to improving healthcare infrastructure and rising medical expenditure.
Key players operating in the chronic kidney disease drugs market include Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharmaceuticals, Inc., AbbVie Inc., ProKidney Corp., Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche AG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., GlaxoSmithKline plc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG, Johnson & Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc., Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Teva Pharmaceutical Industries Ltd., YUHAN, Caladrius Biosciences, Inc., UnicoCell Biomed CO. LTD, Akebia Therapeutics, Inc., Allena Pharmaceuticals, and KBP Biosciences Co., Ltd.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
